SBIR/STTR Research Award
Biodegradable Bone Graft Extender
Award amount
$99,999Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CAMBRIDGE SCIENTIFIC, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Verbatim From Applicant): In order to expand the clinical utility
of bone replacement materials, we are proposing to develop a biodegradable bone
graft extender with inductive capacity. Inductive biodegradable extenders would
be useful in situations where autografts are preferable, yet the patients own
bone stocks are insufficient. This SBIR Phase I project will determine the
feasibility of enhancing the regeneration of skeletal tissues with an extender
fashioned from the biopolymer poly(propylene glycol-co-fumaric acid) (PPF).
This unsaturated polymer can be crosslinked in the presence of effervescent
agents to create an osteoconductive network that can be immediately mixed with
autograft prior to defect filling. In Phase I we will seek to develop
polymer/bone combinations that demonstrate in vitro and in vivo durability over
time, while supporting bone formation equivalent to traditional autologous bone
grafting. Phase II would then address research objectives directed towards
resolution of the clinical dilemma where autologous bone graft is recognized as
the preferable "gold standard," but may not be available in sufficient
quantities. This composite could have biological properties that are superior
to the cortico-cancellous allogeneic bone chips routinely used in this
situation. Osteoinductive autograft material used in conjunction with a highly
osteoconductive, yet resorbable, scaffold would be attractive for both
induction and expansion of new bone formation.
PROPOSED COMMERCIAL APPLICATION:
Bone grafts are used in over 425,000 musculoskeletal operations annually. Overall, 80% of
the bone grafts are used in orthopaedic and spine surgery. Autografts are the preferred
grafting material, but sometimes the patient's own bone stocks are deficient. It is estimated
that synthetic bone replacement materials are used in only 25,000 - 35,000 of clinical grafting
procedures because they are primarily only osteoconductive. If autogenous grafts could be
easily extended via a resorbable osteoconductive material, market acceptance would follow.
Technology keywords
Not reported